Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Bolt Biotherapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 24 | 23 | −1 |
| Shares | 613.3K | 596.5K | −16.7K (−2.7%) |
| Value | $2.49M | $2.31M | −$178.2K (−7.2%) |
New holders (2)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| GWM Advisors LLC | 2,530 | $9.74K | 0.00% |
| Citigroup Inc | 41 | $158 | 0.00% |
Sold out (3)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 42,581 | $172.0K |
| Susquehanna International Group, LLP | 11,657 | $47.1K |
| Vanguard Global Advisers, LLC | 24 | $97 |